About Upadacitinib
Class: | Janus kinase (JAK) inhibitor
Use: | Upadacitinib is indicated for the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more TNF blockers. It is also used for ulcerative colitis.
Adult dose: | The standard adult dose is 15 mg taken orally once daily. The dose may vary based on the specific condition being treated and th
Drug Class
Janus kinase (JAK) inhibitor
Uses & Indications
Upadacitinib is indicated for the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more TNF blockers. It is also used for ulcerative colitis.
Storage Requirements
Store at room temperature, between 20°C to 25°C (68°F to 77°F). Protect from moisture and keep in the original container.
Manufacturer & Packaging
Manufacturer: AbbVie Deutschland GmbH & Co. KG, GERMANY
Package Size
30's HDPE Bottle
Price & Supplier
Price in UAE: AED 5789.00
Dosage Information
Adult Dose
The standard adult dose is 15 mg taken orally once daily. The dose may vary based on the specific condition being treated and the patient's response to therapy.
Pediatric Dose
Upadacitinib is not typically recommended for pediatric use as safety and efficacy have not been established in patients under 18 years of age.
Side Effects
Common side effects include upper respiratory tract infections, nausea, cough, fever, increased liver enzymes, and headache.
Contraindications & Precautions
Contraindicated in patients with known hypersensitivity to upadacitinib or any of its excipients. It should not be used in patients with active tuberculosis, serious infections, or severe hepatic impairment.
Important Warnings
Serious infections, malignancies, and thrombosis have been reported with JAK inhibitors. Patients should be monitored for signs of infection during and after treatment. Upadacitinib may increase the risk of cardiovascular events and should be used with caution in patients with cardiovascular risk factors. Regular monitoring of blood counts and liver enzymes is recommended.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.